Terminated

2

205

Europe, US, RoW

ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda

Seagen Inc., Merck Sharp & Dohme LLC

Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma

11/23

11/23